L. Mao

发表

An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study

G. Gharabawi, Young Zhu, R. Lasser, 2005, Schizophrenia Research.

Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.

B. Pollock, B. Mulsant, L. Tune, 2004, The Journal of clinical psychiatry.

Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications

G. Gharabawi, R. Lasser, L. Mao, 2004, Schizophrenia Research.

Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials.

J. Hulihan, M. Láinez, F. Freitag, 2008, Pain medicine.

Pmh5 Rehospitalization After Discontinuation of Paliperidone Er in Patients With Schizophrenia

J. Pesa, L. Mao, J. Wu, 2008 .

Allodynia‐Associated Symptoms, Pain Intensity and Time to Treatment: Predicting Treatment Response in Acute Migraine Intervention

R. Cady, J. Hulihan, A. Fisher, 2009, Headache.

The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials

E. Loder, C. Dahlöf, M. Rupnow, 2007, Health and quality of life outcomes.

Characteristics of Migraine Attacks and Responses to Almotriptan Treatment: A Comparison of Menstrually Related and Nonmenstrually Related Migraines

R. Cady, D. Biondi, M. Diamond, 2008, Headache.

Change in employment status over 52 weeks in patients with schizophrenia: an observational study

R. Dirani, C. Kozma, L. Mao, 2011, Current medical research and opinion.

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

R. Dirani, C. Kozma, C. Crivera, 2011, BMC psychiatry.

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

R. Dirani, C. Kozma, C. Crivera, 2011, BMC psychiatry.

Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study

L. Alphs, J. Bermak, L. Mao, 2017, Schizophrenia Research.

Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

J. Lindenmayer, L. Alphs, C. Benson, 2015, The Journal of clinical psychiatry.

Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials*

P. Janicak, Jasmanda Wu, L. Mao, 2008, Current medical research and opinion.

Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.

L. Alphs, D. Henderson, S. Deutsch, 2014, Clinical schizophrenia & related psychoses.

Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new‐onset epilepsy: A randomized double‐blind clinical trial

D. Naritoku, J. Hulihan, F. Wiegand, 2010, Epilepsia.

Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.

R. Bergman, C. Nemeroff, L. Phillips, 2008, Journal of psychiatric research.

Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study.

Philip D. Harvey, G. Gharabawi, R. Mahmoud, 2007, The Journal of clinical psychiatry.

Topiramate for treating alcohol dependence: a randomized controlled trial.

D. Ciraulo, K. Mann, F. Wiegand, 2007, JAMA.

The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine

S. Silberstein, R. Cady, J. Hulihan, 2007, Headache.

Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent‐onset versus more chronic schizophrenia and a history of criminal justice system involvement

L. Alphs, C. Bossie, L. Mao, 2015, Early intervention in psychiatry.

Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial.

D. Ciraulo, K. Mann, F. Wiegand, 2008, Archives of internal medicine.

Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT® Early Migraine Intervention Study)

R. Cady, N. Mathew, T. Smith, 2007, Headache.

Long‐Term, Open‐Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents

D. Biondi, A. Pakalnis, E. Vasconcellos, 2008, Headache.

Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension

C. Kozma, L. Mao, C. Canuso, 2010, Annals of general psychiatry.

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

L. Alphs, E. Muser, C. Kozma, 2015, Journal of medical economics.

A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia

L. Alphs, C. Benson, L. Mao, 2016, Schizophrenia Research.

Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.

J. Hulihan, L. Alphs, L. Mao, 2014, The Journal of clinical psychiatry.

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

Philip D. Harvey, G. Gharabawi, J. Napolitano, 2003, International journal of geriatric psychiatry.

The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia

D. Biondi, K. Joshi, L. Mao, 2018, BMC Psychiatry.

Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia

C. Correll, L. Alphs, Edward Kim, 2016, CNS Spectrums.

Effect of Early Intervention With Almotriptan vs Placebo on Migraine‐Associated Functional Disability: Results From the AEGIS Trial

M. Rupnow, D. Biondi, N. Mathew, 2008, Headache.

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

J. Peuskens, T. Lambert, C. Kozma, 2011, Annals of general psychiatry.

Designing a Benefit-Risk Assessment of Maintenance Therapy with an Oral Versus a Long-Acting Injectable Agent in Schizophrenia

L. Dixon, J. Gold, J. Hulihan, 2010 .

Frequency of schizoaffective disorder in an International patient population with psychotic disorders using the Mini-International Neuropsychiatric Interview

J. Sheehan, C. Kosik‐Gonzalez, A. Kalali, 2010, Schizophrenia Research.

Effect of Early Intervention With Almotriptan vs Placebo on Migraine‐Associated Functional Disability: Results From the AEGIS Trial

M. Rupnow, D. Biondi, N. Mathew, 2008, Headache.